Cyfuse Biomedical KKTSE:4892 +2.99%53 Altman Z-Score is 1.65 as of Jul. 13, 2026, which is 35% below its 10-year median of 2.53. GuruFocus rates TSE:4892 with a GF Score™ of 53/100 and a GF Value™ of 円2,179.63 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 953 Drug Manufacturers companies, Cyfuse Biomedical KK ranks worse than 74.61% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Warning Sign:
Altman Z-score of 1.56 is in distress zone. This implies bankruptcy possibility in the next two years.
Cyfuse Biomedical KK has a Altman Z-Score of 1.65, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Cyfuse Biomedical KK's Altman Z-Score or its related term are showing as below:
TSE:4892'
s Altman Z-Score Range Over the Past 10 Years
Min: 1.56 Med: 2.53 Max: 6.15
Current: 1.56
During the past 6 years, Cyfuse Biomedical KK's highest Altman Z-Score was 6.15. The lowest was 1.56. And the median was 2.53.
Cyfuse Biomedical KK (TSE:4892) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Cyfuse Biomedical KK Altman Z-Score Related Terms
Cyfuse Biomedical KK Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Cyfuse Biomedical KK's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cyfuse Biomedical KK's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cyfuse Biomedical KK Altman Z-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cyfuse Biomedical KK's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Cyfuse Biomedical KK's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Cyfuse Biomedical KK's Altman Z-Score for today is calculated with this formula:
Z
=
1.2
*
X1
+
1.4
*
X2
+
3.3
*
X3
+
0.6
*
X4
+
1.0
*
X5
=
1.2
*
0.7207
+
1.4
*
-0.9401
+
3.3
*
-0.111
+
0.6
*
4.094
+
1.0
*
0.0082
=
1.65
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Cyfuse Biomedical KK (TSE:4892) has a Altman Z-Score of 1.65 as of Jul. 13, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Cyfuse Biomedical KK and its competitors. This is 35% below median its historical median of 2.53. Over the past decade, Cyfuse Biomedical KK's Altman Z-Score has ranged from 1.56 to 6.15. According to the industry distribution chart, Cyfuse Biomedical KK ranks #711 out of 953 companies in the Drug Manufacturers industry, placing it in the top 74.6%.
Is Cyfuse Biomedical KK's Altman Z-Score too high?
Cyfuse Biomedical KK's current Altman Z-Score of 1.65 is 35% below median its 10-year median of 2.53. Over the past 10 years, this metric has ranged from a low of 1.56 to a high of 6.15. The Drug Manufacturers industry median Altman Z-Score is 3.25. Cyfuse Biomedical KK's value of 1.65 is 49.2% below this industry median. Based on the distribution chart, Cyfuse Biomedical KK ranks #711 out of 953 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cyfuse Biomedical KK has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cyfuse Biomedical KK's Altman Z-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cyfuse Biomedical KK ranks #711 out of 953 companies for Altman Z-Score. This places Cyfuse Biomedical KK in the lower half of its industry. The industry median Altman Z-Score is 3.25. Cyfuse Biomedical KK's value of 1.65 is 49.2% below this benchmark. Historically, Cyfuse Biomedical KK's own Altman Z-Score has ranged from 1.56 to 6.15 over the past decade. While the company's 10-year median is 2.53 vs. the industry median of 3.25, Cyfuse Biomedical KK has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Drug Manufacturers company?
The median Altman Z-Score among Drug Manufacturers companies is 3.25, based on 953 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cyfuse Biomedical KK's current Altman Z-Score of 1.65 is 49.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Cyfuse Biomedical KK and its competitors. For the Drug Manufacturers industry, the median Altman Z-Score is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cyfuse Biomedical KK's current Altman Z-Score is 1.65, which is 35% below median its own 10-year median of 2.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyfuse Biomedical KK stock overvalued right now?
Based on GuruFocus' analysis, Cyfuse Biomedical KK (TSE:4892) is currently considered Possible Value Trap. The stock's GF Value™ is 円2,179.63, compared to a current price of 円552.00 — trading 74.7% below its estimated fair value. The current Altman Z-Score is 1.65, which is 35% below median its 10-year median of 2.53 and 49.2% below the Drug Manufacturers industry median of 3.25. Cyfuse Biomedical KK's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Cyfuse Biomedical KK (TSE:4892), the current Altman Z-Score is 1.65 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cyfuse Biomedical KK (TSE:4892) Overvalued in 2026?
Based on GuruFocus' analysis, Cyfuse Biomedical KK stock appears to be undervalued.
The current stock price of 円552.00 is trading 74.7% below its estimated GF Value™ of 円2,179.63.
GuruFocus considers Cyfuse Biomedical KK to be Possible Value Trap.
Key valuation signals for TSE:4892:
Altman Z-Score: 1.65 (35% below median its 10-year median of 2.53)
GF Value™: 円2,179.63 vs. price of 円552.00 (74.7% below fair value)
Industry Position: 49.2% below the Drug Manufacturers median (#711 of 953)
No single metric tells the full story. See the TSE:4892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cyfuse Biomedical KK is engaged in the development, manufacturing, and sales of regenerative medicine-related products. The company focuses on delivering three-dimensional tissues and organs created solely from cells as new 3D cell products to medical fields, including regenerative medicine and drug discovery, through the practical application of three-dimensional cell stacking technology. It is engaged in multifaceted development in the following areas: regenerative medicine, drug discovery support, and the device domain, including the development and sales of 3D cell stacking system equipment, such as bio 3D printers equipped with the company's platform technology.
53GF Score
Get the complete analysis for TSE:4892
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4892 has been successfully added to your 
